Improving the evaluation of new cancer therapies to expedite patient access

点击翻译按钮获取中文摘要

The government funds cancer drugs, but drugs have to provide value for money to Australian taxpayers. Most proposed cancer drugs provide a benefit to patients but reaching agreement on how much the government will pay for these drugs often delays access by months, and often over a year due to uncertainty regarding drugs’ long-term effects. This research will test methods and develop guidelines to reduce this uncertainty and provide earlier access to new cancer drugs.